2026-08-29T19:28:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/185212024-09-21T21:16:19Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Fernandez Rivera, Constantino author Calvo Rodríguez, María author Poveda, José Luís author Pascual, Julio author Crespo, Marta author Gomez, Gonzalo author Cabello Pelegrin, Sheila author Paul, Javier author Lauzurica, Ricardo author Perez Mir, Mònica author Moreso, Francesc author Perelló, Manel author Andres, Amado author González, Esther author Fernandez, Ana author Mendiluce, Alicia author Fernández Carbajo, Beatriz author Sanchez Fructuoso, Ana author Calvo, Natividad author Suarez, Alejandro author Bernal Blanco, Gabriel author Osuna, Antonio author Ruiz-Fuentes, M Carmen author Melilli, Edoardo author Montero Perez, Nuria author Ramos, Ana author Fernández, Beatriz author López, Verónica author Hernandez, Domingo author Better study author 2021-12-17 Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P  10.1111/ctr.14550 1399-0012 Clinical transplantation http://hdl.handle.net/10668/19932 34851532 http://hdl.handle.net/20.500.12105/18521 bioavailability clinical practice pharmacokinetics renal transplantation tacrolimus treatment failure Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.